Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01489K

APPLICATION NO.:

10/057,323

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT:

Harry R. Davis et al.

FILING DATE:

01/25/2002

GROUP:

1617

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SH	AA	6,030,990	02/29/00	Maeda et al.			
SH	AB	6,166,049	12/26/00	Smith et al.			
SH	AC	2003/0153541	08/14/03	Dudley et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
SH	AE	WO 01/14351	03/01/01	PCT				
	AE	WO 01/34148	05/17/01	PCT				
	AF	WO 01/60807	08/23/01	PCT				
	AG	WO 02/064094	08/22/02	PCT				
	AH	WO 02/08188	01/31/02	PCT				
	AI	WO 02/26729	04/04/02	PCT				
	AJ	WO 03/039542	05/15/03	PCT				
	AK	WO 03/074101	09/12/03	PCT				
SH	AL	WO 03/088962	10/30/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SH	AM	Sorbera et al., Netoglitazone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139
SH	AN	Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259
SH	AO	Berger et al., Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology & Therapeutics</i> , 2002, 4:163-174


EXAMINER

DATE CONSIDERED

2/26/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01489K		SERIAL NO.: 10/057,323	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis, et al.			
				FILING DATE: January 25, 2002		GROUP: 1619	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SH	AA	5,021,461	06/04/91	Robinson et al.			
SH	AB	4,687,777	08/18/87	Meguro et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
SH	AC	WO 97/28149	08/07/97	PCT			
	AD	WO 99/22728	05/14/99	PCT			
	AE	WO 01/96347	12/20/01	PCT			
	AF	WO 02/26729	04/04/02	PCT			
	AG	WO 02/064094	08/22/02	PCT			
	AH	WO 95/35277	12/28/95	PCT			
	AI	WO 02/50027	06/27/02	PCT			
	AJ	WO 02/50060	06/27/02	PCT			
	AK	WO 02/50068	06/27/02	PCT			
	AL	WO 99/08501	02/25/99	PCT			
	AM	WO 94/26738	11/24/94	PCT			
	AN	EP 1 036 563 A1	09/20/00	EPO			
	AO	EP 0 753 298 A1	01/15/97	EPO			
SH	AP	FR 1103113	10/31/55	FRANCE			X (abs.)
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
SH	AQ	Stuart B. Rosenblum et al., Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption, <i>J. Med. Chem.</i> 41:973-980 (1998)					
	AR	Gilbert R. Thompson et al., Novel lipid-regulating drugs, <i>Exp. Opin. Invest. Drugs</i> 9(11):2619-2628 (2000)					
	AS	T. Kosoglou et al., Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects on Apo CIII and LDL Subfractions, <i>Atherosclerosis</i> 2:89 (2001)					
	AT	Harry R. Davis et al., The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs, <i>Metabolism</i> 50 (10):1234-1241 (2001)					
	AU	Study Showed Ezetimibe Significantly Reduced Levels of LDL Cholesterol or "Bad" Cholesterol in Patients, Schering-Plough Press Release					
	AV	T. Kosoglou et al., Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe, <i>Atherosclerosis</i> (2):38 (2001)					
	AW	Remington's Pharmaceutical Sciences, 18 th ed. 1990 p. 1319, 1633-1647					
	AX	Baker S G et al., Treatment of homozygous familial hypercholesterolaemia with probucol, <i>South African Medical Journal</i> (1982)					
SH	AY	R. Milanese et al., Xantomi E ipercolesterolemia: Prevalenza, Diagnosi e Terapia, <i>Chron. Derm.</i> 455-61 (1990)					
EXAMINER 				DATE CONSIDERED 2/26/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/057,323
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT: Harry R. Davis, et al.	
				FILING DATE: 01/25/2002	GROUP: 1619

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
					YES	NO	
SH AL WO 99/08501	2/25/99	PCT					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
SH	AQ	"Study showed ezetimibe significantly reduced levels of LDL cholesterol or "bad" cholesterol in patients" <i>Schering Press Release</i> 1-3 (2001)
SH	AR	Kosoglou <i>et al.</i> , "Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe" <i>Atherosclerosis</i> (2):3(2001)
SH	AS	Davis <i>et al.</i> , "The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs" <i>Metabolism</i> 50(10) :1234-1241(2001)
	AT	
	AU	
	AV	

EXAMINER 	DATE CONSIDERED 2/26/04
--------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1

FORM PTO/BD-15

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:

CV01489K

SERIAL NO.:

10/057,323

APPLICANT:

Harry R. Davis, et al.

FILING DATE:

01/25/2002

GROUP:

1619

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
SH	AL WO 95/35277	12/28/95	PCT	C07D	205/08		
	AM						
	AN						
	AO						
	AP						


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SH	AQ	Thompson, G.R. et al., "Novel lipid-regulating drugs" <i>Expert Opinion on Investigational Drugs</i> 9(11):2619-2628 (2000), XP008011782 abstract; figure 8
SH	AR	Kosoglou, T. et al., "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions" <i>Atherosclerosis</i> 2:89 (2001), XP1132089 abstract
	AS	
	AT	
	AU	
	AV	

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

MAY 06 2003
Sheet 1 of 1

PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CV01489K TECH CENTER 1600/2900 10/057,323
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			APPLICANT: Harry R. Davis, et al.
			FILING DATE: January 25, 2002 GROUP: 1619
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
34	AA	Exhibit A: SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary	
	AB	Exhibit B: SCH 58235 (ezetimibe), Drug Formulation Development Summary	
	AC	Exhibit C: SCH 58235 (ezetimibe), Drug Formulation Development Summary	
	AD	Exhibit D: SCH 58235 (ezetimibe), Drug Formulation Development Summary	
	AE	Exhibit E: SCH 58235 (ezetimibe), Drug Formulation Development Summary	
	AF	Exhibit F: SCH 58235 (ezetimibe), Drug Formulation Development Summary	
	AG	Exhibit G: SCH 58235 (ezetimibe), Drug Formulation Development Summary	
	AH	Exhibit H: SCH 58235 (ezetimibe), Drug Formulation Development Summary	
	AI	Exhibit 1: Master Sheet for the SCH 58235 and Lovastatin Research Study, <i>Schering-Plough Research Institute</i> (Protocol No. C906-411), page 1576-1585	
	AJ	Exhibit 2: Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, <i>Peninsular Testing Corporation</i> , page 106-112.	
	AK	Exhibit 3: Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," <i>Schering-Plough Research Institute</i> (Protocol No. C98-010), page 1558-1566	
	AL	Exhibit 4: Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, <i>Peninsular Testing Corporation</i> , page 124-130	
58	AM	Exhibit 5: Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," <i>Schering-Plough Research Institute</i> , page 1-8	
EXAMINER		DATE CONSIDERED	
		2/26/04	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01489K		SERIAL NO.: 10/057,323	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis et al.			
				FILING DATE: January 25, 2002		GROUP: 1617 1619	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SH	AA	US2003/0013729	01/16/03	Iqbal et al.	514		
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
SH	AL	WO 03/018024	03/06/03	PCT	A61K	31/55	
	AM	WO 03/018059	03/06/03	PCT	A61K	45/06	
SH	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
EXAMINER <i>Sankar</i>				DATE CONSIDERED 2/26/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							


RECEIVED

APR 11 2003

TECH CENTER 1600/2900



FORM PTO 4449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01489K		SERIAL NO.: 10/057,323	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis et al.			
				FILING DATE: January 25, 2002		GROUP: 1617 1619	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
SH	AL	WO96/19450	06/27/96	PCT	C07D	205/08	
	AM	WO02/081454	10/17/02	PCT	C07D	239/36	
	AN	WO02/26729	04/04/02	PCT	C07D	311/66	
SH	AO	WO02/64094	08/22/02	PCT	A61K		
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
SH	AQ	Gilber R. Thompson et al., Novel lipid-regulating drugs, Ashley Publications Ltd. ISSN 1354-3784, 2000, pp. 2619-2628					
	AR	Belamarich P.F. et al., Response to diet and cholestyramine in a patient with sitosterolemia, Pediatrics, ISSN 0031-4005, Dec. 1990					
SH	AS	Salen G. et al., Lethal atherosclerosis associated with abnormal plasma and tissue sterol composition in sitosterolemia with xanthomatosis, Journal of lipid research, ISSN 0022-2275, Sept. 1985					
	AT						
	AU						
	AV						
EXAMINER <i>Santhosh</i>				DATE CONSIDERED 2/26/03			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							




Sheet 1 of 8

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01489K		SERIAL NO.: 10/057,323	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis et al.			
				FILING DATE: January 25, 2002		GROUP: 1619	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
5H	FQ	WO 97/21676	06/19/97	PCT	C07D	205/09	
	FR	WO 97/41098	11/06/97	PCT	C07D	205/09	
	FS	WO 00/23415	04/27/00	PCT	C07C	69/734	
	FT	WO 00/23416	04/27/00	PCT	C07C	69/734	
	FU	WO 00/23425	04/27/00	PCT	C07D	209/80	
	FV	WO 00/23445	04/27/00	PCT	C07D	471/12	
	FW	WO 00/23451	04/27/00	PCT	C07D	487/14	
	FX	WO 00/28981	05/25/00	PCT	A61K	31/00	
	FY	WO 00/31548	06/02/00	PCT	G01N	33/68	
	FZ	WO 00/32189	06/08/00	PCT	A61K	31/415	
	GA	WO 00/34240	06/15/00	PCT	C07D	205/08	
	GB	WO 00/37057	06/29/00	PCT	A61K	9/48	
	GC	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)
	GD	WO 00/38721	07/06/00	PCT	A61K	45/06	
	GE	WO 00/38722	07/06/00	PCT	A61K	45/06	
	GF	WO 00/38723	07/06/00	PCT	A61K	45/06	
	GG	WO 00/38724	07/06/00	PCT	A61K	45/06	
	GH	WO 00/38725	07/06/00	PCT	A61K	45/06	
	GI	WO 00/38726	07/06/00	PCT	A61K	45/06	
	GJ	WO 00/38727	07/06/00	PCT	A61K	45/06	
	GK	WO 00/38728	07/06/00	PCT	A61K	45/06	
	GL	WO 00/38729	07/06/00	PCT	A61K	45/06	
	GM	WO 00/40247	07/13/00	PCT	C07D	265/26	
	GN	WO 00/45817	08/10/00	PCT	A61K	31/505	
	GO	WO 00/50392	08/31/00	PCT	C07C	323/52	X(abs.)
	GP	WO 00/53149	09/14/00	PCT	A61K		
	GQ	WO 00/53173	09/14/00	PCT	A61K	31/22	
	GR	WO 00/53563	09/14/00	PCT	C07C	59/92	X(abs.)
	GS	WO 00/56403	09/28/00	PCT	A61P	9/10	
	GT	WO 00/57859	10/05/00	PCT	A61K	9/48	
	GU	WO 00/57918	10/05/00	PCT	A61K	47/44	
	GV	WO 00/60107	10/12/00	PCT	C12P	17/10	
	GW	WO 00/63153	10/26/00	PCT	C07C	69/734	
	GX	WO 00/63161	10/26/00	PCT	C07C	237/30	
	GY	WO 00/63190	10/26/00	PCT	C07D	265/38	
	GZ	WO 00/63196	10/26/00	PCT	C07D	277/04	
	HA	WO 00/63209	10/26/00	PCT	C07D	471/04	
	HB	WO 00/63703	10/26/00	PCT	G01N	33/92	
	HC	WO 00/69412	11/23/00	PCT	A61K	9/127	
	HD	WO 00/69445	11/23/00	PCT	A61K	31/785	
	HE	WO 00/72825	12/7/00	PCT	A61K	9/14	
5H	HF	WO 00/72829	12/07/00	PCT	A61K	9/48	

Parhys 2/26/04


RECEIVED
APR 09 2003
TECH CENTER 1400 2900



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					ATTY. DOCKET NO.: CV01489K		SERIAL NO.: 10/057,323	
					APPLICANT: Harry R. Davis et al.			
					FILING DATE: January 25, 2002		GROUP: 1619	
54	HG	WO 00/75103	12/14/00	PCT	C07C	235/60	(abs.)	
	HH	WO 00/76482	12/21/00	PCT	A61K	9/48		
	HI	WO 00/76488	12/21/00	PCT	A61K	31/00		
	HJ	WO 00/78312	12/28/00	PCT	A61K	31/421		
	HK	WO 00/78313	12/28/00	PCT	A61K	31/422		
	HL	WO 01/00579	01/04/01	PCT	C07D	213/65		
	HM	WO 01/00603	01/04/01	PCT	C07D	277/24		
	HN	WO 01/08686	02/08/01	PCT	A61K	31/495		
	HO	WO 01/12176	02/22/01	PCT	A61K	31/16		
	HP	WO 01/12187	02/22/01	PCT	A61K	31/404		
	HQ	WO 01/12612	02/22/01	PCT	C07D	257/04		
	HR	WO 01/14349	03/01/01	PCT	C07D	277/34	X(abs.)	
	HS	WO 01/14350	03/01/01	PCT	C07D	277/34	X(abs.)	
	HT	WO 01/14351	03/01/01	PCT	C07D	277/34	X(abs.)	
	HU	WO 01/15744	03/08/01	PCT	A61K	49/00		
	HV	WO 01/16120	03/08/01	PCT	C07D	263/32		
	HW	WO 01/17994	03/15/01	PCT	C07D	413/12		
	HX	WO 01/18210	03/15/01	PCT	C12N	15/12		
	HY	WO 01/21181	03/29/01	PCT	A61K	31/675	X(abs.)	
	HZ	WO 01/21259	03/29/01	PCT	A61P			
	IA	WO 01/21578	03/29/01	PCT	C07C	235/60	X(abs.)	
	IB	WO 01/21647	03/29/01	PCT	C07K	14/00		
	IC	WO 01/22962	04/05/01	PCT	A61K	31/435		
	ID	WO 01/25225	04/12/01	PCT	C07D	317/18		
	IE	WO 01/25226	04/12/01	PCT	C07D	327/04		
	IF	WO 01/30343	05/03/01	PCT	A61K	31/40		
	IG	WO 01/32161	05/10/01	PCT	A61K	31/00		
	IH	WO 01/35970	05/25/01	PCT	A61K	35/76		
	II	WO 01/40192	06/07/01	PCT	C07D	217/26	X(abs.)	
	IJ	WO 01/45676	06/28/01	PCT	A61K	9/24		
	IK	WO 01/49267	07/12/01	PCT	A61K	9/14		
	IL	WO 01/64221	09/07/01	PCT	A61K	31/52		
	IM	WO 01/76632	10/18/01	PCT	A61K	45/06		
	IN	WO 02/50090	06/27/02	PCT	C07H	15/26		
	IO	WO 02/058696	08/01/02	PCT	A61K	31/397		
	IP	WO 02/058731	08/01/02	PCT	A61K	45/06		
	IQ	WO 02/058732	08/01/02	PCT	A61K	45/06		
	IR	WO 02/058733	08/01/02	PCT	A61K	45/06		
	IS	WO 02/058734	08/01/02	PCT	A61K	45/06		
	IT	WO 02/058685	08/01/02	PCT	A61K	31/00		
	IU	WO 02/064130	08/22/02	PCT	A61K	31/195		
	IV	WO 02/064549	08/22/02	PCT	C07C	275/34		
	IW	WO 02/064664	08/22/02	PCT	C08G	77/02		
	IX	WO 02/072104	09/19/02	PCT	A61K	31/54		
	IY	WO 02/081454	10/17/02	PCT	C07D	239/36		
	IZ	WO 02/26729	04/04/02	PCT	C07D	311/66		
5H	JA	WO 02/064094	08/22/02	PCT	A61K			

RECEIVED
APR 01 2003
FBI CENTER 16012900

Sanhuphi 2/26/04



Sheet 3 of 8


TECH CENTER 1600 2200

APR 08 2003

RECEIVED

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/057
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Harry R. Davis et al.	
(Use several sheets if necessary)				FILING DATE:	GROUP:
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
SH	JB	Vaccaro, W.D. et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" <i>Bioorganic & Medicinal Chemistry Ltrs., Oxford, G.B.</i> , 8:313-318 (1998)			
	JC	Vaccaro, W.D. et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", <i>Bioganic & Medicinal Chem. Ltrs. Oxford, G.B.</i> 8:319-322 (1998)			
	JD	H. Davis et al., "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E Knockout Mice", <i>Arterioscler, Thromb. Vasc. Biol</i> 21:2032-2038, (Dec. 2001)			
	JE	Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", <i>Chemical Abstracts No. 15</i> , 86 (April 11, 1997)			
	JF	Otto et al., "Stereochemistry of dehydration and halogenation of α^* and α^* isomeric 3-(α -hydroxybenzyl)-1,4 diphenyl-2 azetidinones, <i>Chemical Abstracts No. 19</i> , 99 (Nov. 7, 1983)			
	JG	T. Durst et al., "Metallation of N-Substituted β -Lactams. A Method of the Introduction of 3-substituents into β -Lactams" <i>Canadian Journal of Chemistry</i> , 50:3196-3201 (1971)			
	JH	Nobuki, O. et al., "Stereoselective syntheses of β -lactam derivatives by ultrasound promoted Reformatskii reaction" <i>Chemical Abstracts No. 106</i> , 17 (April 27, 1987)			
	JI	M. Hoekman, et al., "Synthesis of Homologues of 4,5-Dihydroxy-and 4-Hydroxy-5-oxohexanoic Acid γ -Lactones", <i>J. Agric. Food Chem.</i> , 30:920-024 (1982)			
	JJ	H. Otto et al. "Darstellung und Stereochemie von 3-(α -Hydroxybenzyl)-1,4-diphenyl-2-azetidinonen", <i>Liebigs Ann. Chem.</i> 1152-1161 (1983)			
	JK	G. George et al. "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" <i>Tetrahedron Letters</i> , 26:3903-3906 (1985)			
	JL	Hart et al. "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", 26 <i>Tetrahedron Letters</i> , 45:5493-5496 (1985)			
	JM	Panfil, I. et al. "Synthesis of β -Lactams from α , β -Unsaturated Sugar δ -Lactones" 24 <i>Heterocycles</i> 6:1609-1617 (1986)			
	JN	D. Roger Illingworth, "An Overview of Lipid-Lower Drugs" <i>Drugs</i> 36:63:71 (1988)			
	JO	Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" <i>Circulation</i> 80:1101-1114 (1989)			
	JP	B. Ram et al. "Potential Hypolipidemic agents: Part V", 29B <i>Indian J. Chem.</i> 1134-37 (1990)			
	JQ	Schnitzer-Polokoff, R. et al., "Effects of Acyl-CoA: Choleseraol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" <i>Comp. Biochem. Physiol.</i> 99A:665-670 (1991)			
	JR	Horie, M. et al, "Hypolipidemic effects of NB-598 in dogs" <i>Atherosclerosis</i> 88:183-192 (1991)			
	JS	Baxter, A., "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", <i>The Journal of Biological Chemistry</i> 267:11705-11708 (1992)			
	JT	Summary Factfile, "Anti-Antherosclerotic Agents" <i>Current Drugs Ltd.</i> (1992)			
	JU	Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β -tigogenin cellobioside (CP-88818; tiqueside) 1" <i>Journal of Lipid Research</i> 34:377-395 (1993)			
SH	JV	Salisbury, B. et al., "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" <i>Atherosclerosis</i> 115:45-63 (1995)			

Carbapenem 2/26/04



Sheet

4

TECH CENTER

APR 08 2003

RECEIVED

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01489K	SERIAL 10/057,333
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			APPLICANT: Harry R. Davis et al.	
			FILING DATE: January 25, 2002	
			GROUP: 1619	
541	JW	Clader, J. W. et al., "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Viro Activity" <i>Journal of Medicinal Chemistry</i> 38:1600-1607 (1995)		
	JX	Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" <i>Atherosclerosis</i> pp. 311-315 (1995)		
	JY	Vaccaro, W, et al, "2-Azetidinone Cholesterol Absorption Inhibitors; Increased Potency by Substitution of the C-4 Phenyl Ring", <i>Bioorg. & Med. Chem.</i> 6:1429-1437 (1998)		
	JZ	G. Wu et al, "A Novel One-Step Diastereo- and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (4/21/99).		
	KA	B. Staels, "New Roles for PPARS in Cholesterol Homeostasis", <i>Trends in Pharmacological Sciences</i> , 22:9 p. 444 (Sept. 2001)		
	KB	Abbott et al, "Tricor® Capsules, Micronized", <i>Physicians Desk Reference</i> , January 8, 2001.		
	KC	M. Feher et al., 1991, <i>Lipids and Lipid Disorders</i> , p.1-87 (1991).		
	KD	M. Ricote et al., "New Roles for PPARs in Cholesterol Homeostasis", <i>Trends in Pharmacological Science</i> , Vol. 22, No. 9 44-443 (2001)		
	KE	C. Dujovne et al, "Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a multicenter Dose-Ranging Study", <i>J. Clin. Pharm.</i> 41:1 70-78 (Jan. 2001)		
	KF	W. Oppolzer et al., "Asymmetric Diels - Alder Reactions, Facile Preparation and Structure of Sulfonamido - Isobornyl Acrylates", <i>Tetrahedron Letters</i> No. 51, 25:5885-5888 (1984).		
	KG	M. Davidson et al., "Colesevelam Hydrochloride: a non-absorbed, polymeric cholesterol lowering agent", <i>Expert Opinion Investigating Drugs</i> , 11:2663-71, (Nov. 2000)		
	KH	M. Davidson et al., "Colesevelam hydrochloride (cholestagel): a new, potent bileacid sequestrant associated with a low incidence of gastrointestinal effects", 159 <i>Arch. Intern. Med.</i> 16 1893-900 (Sept. 1999)		
	KI	I. Wester, "Cholesterol - Lowering effect of plant sterols", <i>Euro. J.Lipid, Sci. Tech.</i> 37-44 (2000).		
	KJ	A. Andersson et al., "Cholesterol -lowering effects of a stanol ester-containing low fat margarine used in conjunction with a strict lipid-lowering diet", 1 <i>European Heart. J. Supplements</i> S80 - S90 (1999)		
	KK	H. Gylling et al, "Reduction of Serum Cholesterol in Postmenopausal Women with Previous Myocardial Infarction and Cholesterol Malabsorption induced by Dietary Sitostanol Ester Margarine, 96 <i>Circulation</i> 12 4226-4231 (Dec. 16, 1997)		
	KL	T. Miettinen et al, "Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population", <i>New England Journal of Med.</i> 333 1308-1312 (Nov. 16, 1995)		
	KM	T. Bocan et al., "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", <i>Arterioscler Thromb Vasc. Biol.</i> 70-79 (Jan. 2000)		
	KN	M. Van Heek et al., "In Vivo Metabolism - Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the identification of the active metabolites of SCH48461," 283 <i>J. Pharma and Experimental Therapeutics</i> 1 157-163 (1997)		
541	KO	H. Davis et al., "The Cholesterol Absorption Inhibitor Ezetimibe Inhibits the Development of Atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets," 151 <i>Atherosclerosis</i> 1:133 (July 2000)		


Carbapent 2/26/04

Sheet 5TECH CENTER
APR 03 2003
20012900


RECEIVED

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/057-323
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Harry R. Davis et al.	
(Use several sheets if necessary)				FILING DATE: January 25, 2002	GROUP 1619
541	KP	L. Nguyen et al., "Unexpected Failure of Bile Acid Malabsorption to Stimulate Cholesterol Synthesis in Sitosterolemia with Xanthomatosis", <i>10 Atherosclerosis</i> 2, 289-297 (1990)			
	KQ	L. Nguyen et al., "Regulation of Cholesterol Biosynthesis in Sitosterolemia: effects of lovastatin, Cholestyramine, and dietary sterol restriction," <i>32 J. Lipid Res.</i> 1941-1948 (1991)			
	KR	M. Cobb et al., "Sitosterolemia: Opposing Effects of cholestyramine and Lovastatin on Plasma Sterol Levels in a Homozygous Girl and Her Heterozygous Father," <i>45 Metabolism</i> 6 673-679 (June 1996)			
	KS	M. Huettinger et al., "Hypolipidemic Activity of HOE-402 is mediated by Stimulation of the LDL Receptor Pathway", <i>13 Arteriosclerosis and Thrombosis</i> 7 1005-1012 (July 1993).			
	KT	J. Best et al., "Diabetic Dyslipidaemia", <i>59 Drugs</i> 5 1101-1111 (May 2000)			
	KU	P. Chong, et al, "Current, New and Future Treatment in Dyslipidaemia and Atherosclerosis", <i>60 Drugs</i> 1 55-93 (July 2000)			
	KV	M. Brown et al, "A Receptor - Mediated Pathway for Cholesterol Homeostasis", <i>232 Science</i> 34-47 (April 4, 1986)			
	KW	L. Lipka et al., "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by SCH 58235: Pooled Analysis of Two Phase II Studies", <i>JACC</i> 257A (Feb. 2000)			
	KX	Medical Economics, Co., Inc., <i>Physician's Desk Reference</i> , 207-208, 2054 (55 th Ed. 2001)			
	KY	K. Fassbender et al., "Simvastatin Strongly Reduces Levels of Alzheimer's Disease β -Amyloid Peptides A β 42 and A β 40 in vitro and in vivo", <i>PNAs Early Edition</i> , www.phas.org/cgi/doi/10.1073/phas.081620098 (2001)			
	KZ	Andrx Announces Results of Alzheimer's Disease Clinical Study", <i>Andrx Corporate Release</i> (April 11, 2001)			
	LA	Andrx (ADRX): Pos Phase II Results Using Avicor in Alzheimer's: Str Buy; \$130", <i>US Bancorp Piper</i> , April 12, 2001			
	LB	Statins May Protect Against Alzheimer's Disease; much research needed", <i>Geriatrics</i> February 2001			
	LC	Dementia and Statins", <i>The Lancet</i> March 17, 2001			
	LD	Research & Development: Andrx Says Cholesterol Drug May Treat Alzheimers", <i>Reuters</i> April 11, 2001			
	LE	Cholesterol Drugs Ease Alzheimer's Damage; www.usatoday.com April 10, 2001			
	LF	Lovastatin XL of Use in Alzheimer's? News Edge (May 2, 2001)			
	LG	L. Refolo et al, "Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model, <i>Neurobiology of Disease</i> 321-331 (2000)			
	LH	D. Kang et al., "Modulation of Amyloid β -protein Clearance and Alzheimer's Disease Susceptibility by the LDL Receptor - Related Protein Pathway", <i>Journal of Clinical Investigation</i> 106:9, 1159-1166 (Nov. 2000)			
	LI	Y.A. Kesaniemi, "Intestinal Cholesterol Absorption Efficiency in Man is Related to Apoprotein E Phenotype", <i>J. Clin. Invest.</i> 80(2) 578-81 (Aug. 1987)			
	LJ	J. Busciglio et al., "Generation of β -amyloid in the secretory pathway in neuronal and nonneuronal cells", <i>90 Proc. Nat'l. Acad. Sci, USA</i> , 2092-2096 <i>Neurobiology</i> (March 1993)			
	LK	L. Farrer et al., "Assessment of Genetic Risk for Alzheimer's Disease Among first Degree Relatives", <i>Annals of Neurology</i> 25:5, 485-493 (May 1989)			
542	LL	A. Goate et al., "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", <i>349 Nature No. 6311</i> , 704-706 (Feb. 21, 1991)			

2/26/04




Sheet 6




FORM PTO-1432		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/05/23
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Harry R. Davis et al.	
(Use several sheets if necessary)				FILING DATE: January 25, 2002	GROUP: 1619
SM	LM	D. Mann <i>et al.</i> , "The Pattern of Acquisition of Plaques and Tangle in the Brains of Patients Under 50 years of Age with Down's Syndrome", 89 <i>J. Neuro. Sci.</i> , 169-179 (Feb. 1989)			
	LN	G. McKhann <i>et al.</i> , "Clinical Diagnosis of Alzheimer's Disease", 34 <i>Neurology</i> No. 7, 939-944 (July 1984)			
	LO	D. Selokoe, "Alzheimer's Disease: Genotypes, Pheontype and Treatments", 275 <i>Science</i> , 630-631 (Jan. 31, 1997)			
	LP	C. Van Duijn, <i>et al.</i> , "Familial Aggregation of Alzheimer's Disease and Related Disorders: A collaborative Re-Analysis of Case-Control Studies", 20 <i>Int'l J. Epidemiology</i> No. 2 (Suppl. 2), 513-520 (1991)			
	LQ	T Nagahara <i>et al.</i> , "Dibasic (Amidcinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", <i>J. Med. Chem</i> 37:1200-1207 (1994)			
	LR	Mellott <i>et al.</i> , "Acceleration of Recombinant Tissue-Type Plasminogen Activator Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistatin, a selective factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <i>Circulation Research</i> , 70:1152-1160 (1992)			
	LS	Sitko <i>et al.</i> , "Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide", <i>Circulation</i> , 85:808-815 (1992)			
	LT	Seymour <i>et al.</i> , 1994, <i>Biochemistry</i> , 33:3949-3959			
	LU	Markwardt, 1994, <i>Thrombosis and Hemostasis</i> , 72:477-479			
	LV	Mendall <i>et al.</i> , "C-Reactive Protein and its relation to cardiovascular risk factor: A population based cross sectional study", <i>BMJ</i> ; 312:1061-1065 (April 27, 1996)			
	LW	Ridker P. <i>et al.</i> , "Prospective Studies of C-Reactive Protein as a risk factor for cardiovascular disease", 46 <i>J. Investig. Med.</i> ; 8:391-395 (1998)			
	LY	Waters, D. <i>et al.</i> , "A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis", <i>Circulation</i> ; 82:1940-1953 (1990)			
	LZ	Fleckenstein, 1985, <i>Cir. Res.</i> Vol 52 (Suppl. 1) 13-16			
	MA	Fleckenstein, 1983, "Experimental Facts and Therapeutic Prospects", <i>John Wiley, New York</i> , pp. 286-313			
	MB	McCall, D., 1985, "Curr. Pract. Cardiol. Vol. 10, 1-11			
	MC	Remington 1995, "The Science and Practice of Pharmacy, (19 th Ed. 1995) p. 963			
	MD	M. Chistie <i>et al.</i> , "Early - Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695", 276 <i>J. Biol. Chem.</i> No. 24; 21562-70 (June 15, 2001)			
	ME	C. Janus <i>et al.</i> , "A β Peptide Immunization Reduces Behavioral impairment and Plaques in a Model of Alzheimer's Disease", 408 <i>Nature</i> 21/28; 979-982 (Dec. 2000)			
	MF	Manual of Laboratory Operations, "Lipid Research Clinics Program Report, Washington, D.C., U.S. Dept. of Health, Education and Welfare Publication; 1:75-628 (1974)			
	MG	Steiner, PM <i>et al.</i> , "Standardization of Micromethods for Plasma Cholesterol, Triglyceride and HDL-Cholesterol with the Lipid Clinic's Methodology [abstract], <i>J. Clin. Chem. Clin. Bichem</i> ; 19:850 (1981)			
	MH	Steele WG, <i>et al.</i> , "Enzymatic Determinations of Cholesterol in High Density Lipoprotein Fractions Prepared by Precipitation Technique, 22 <i>Clin. Chem.</i> ; 1:98-101 (1976)			
SM	MI	Salen <i>et al.</i> , "Increased Sitosterol Absorption, Decreased Removal and Expanded Body Pools Compensate for Reduced Choelsterol Syntheses in Sitosterolemia with Xanthomatosis", <i>J. Lipd Res.</i> ; 30:1319-1330 (1989)			

Sanjay 2/26/04

Sheet 7RECEIVED
APR 8 2003
TECH CENTER 1600 2900

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/057323
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			APPLICANT: Harry R. Davis et al.	
			FILING DATE: January 25, 2002	GROUP: 1619
584	MJ	Lutjohann et al., "Sterol Absorption and Sterol Balance in Phytosterolemia Evaluated by Deuterium-Labeled Sterols: Effect of Sitostanol Treatment", <i>J. Lipid Res.</i> ; 36:8 ; 1763-1773 (1995)		
	MK	Zhang et al., "Calpain Inhibitor I Increases B- Amyloid Peptide by Inhibiting the Degradation of the Substrate of γ - Secretase" 274 J. Biol. Chem. , 13:8966-8972 (1999)		
	ML	Zhang et al., "Biochemical Characterization of the γ -Secretase Activity that Produces B-Amyloid Peptides", <i>Biochemistry</i> 40:5049-5055 (2001)		
	MM	Ida et al., "Analysis of Heterogeneous BA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay", 271 J. Biol. Chem. ; 37:22908-22914 (1996)		
	MN	Lichtlen, P.R. et al., 1990, <i>Lancet</i> , 335:1109-1113		
	MO	Bays et al., "Effectiveness and Tolerability of Ezetimibe in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies", <i>Clinical Therapeutics</i> , 23:1209-1230 (2001)		
	MP	E. Leitersdorf et al., "Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management", <i>European Heart Journal Supplement</i> , 3:E17-E23 (June 2001)		
	MQ	Bauer et al., "Ezetimibe Does not Affect the Pharmacokinetics or Pharmacodynamics of Warfarin", <i>Clinical Pharmacology and Therapeutics</i> , 69:2 p5 (Mar. 6-10, 2001)		
	MR	Keung et al., "Ezetimibe Does Not Affect the Pharmacokinetics of oral Contraceptives", <i>Clinical Pharmacology and Therapeutics</i> , 69:2 p55 (Mar. 6-10, 2001)		
	MS	Kosoglou et al., "Pharmacodynamic interaction between fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs 72nd EAS Congress</i> , p. 38 (May 21-23, 2001)		
	MT	T. Kosoglou et al., "Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects On Apo CII and LDL Subfractions", <i>Posters 11. Lipid Lowering Drugs/Novel, 72nd EAS Congress</i> , p. 89 (May 21-23, 2001)		
	MU	L. Reyderman et al., "Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Gemfibrozil", Presented at XIV Int'l Symp. on Drugs Affecting Lipid Metabolism (DALM) N.Y. (Sept. 9-12, 2001)		
	MV	P. Statkevich et al., "Ezetimibe Does Not Affect the Pharmacokinetics and Pharmacodynamics of Glipizide", <i>Clinical Pharmacology & Therapeutics</i> , 69:67 (March 6-10, 2001)		
	MW	Knopp et al., "Effect of Ezetimibe on Serum Concentrations of Lipid-Soluble Vitamins", <i>Posters 11. Lipid Lowering Drug/Novel 72nd EAS Congress</i> , p. 90 (May 21-23, 2001)		
	MX	Kosoglou et al., "Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs, 72nd EAS Congress</i> , p. 38 (March 6-10, 2001)		
	MY	Bays et al., "Low-Density Lipoprotein Cholesterol Reduction By SCH 58235 (Ezetimibe), A Novel Inhibitor of Intestinal Cholesterol Absorption, in 243 Hypercholesterolemic Subjects: Results of a Dose-Response Study", <i>XII International Symposium on Atherosclerosis, Stockholm, Sweden (June 25-29, 2000)</i>		
	MZ	Castaner et al., "Ezetimibe - Hypolipidemic Cholesterol Absorption Inhibitor", <i>Drugs of the Future</i> , 25(7):679-685 (2000)		
	NA	Lipka et al., "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by Ezetimibe (SCH 58235): Pooled Analysis of Two Phase II Studies", <i>American College of Cardiology Annual Meeting, Anaheim, CA (March 12-15, 2000)</i>		
584	NB	Van Heek et al., "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663", <i>British Journal of Pharmacology</i> , 129:1748-1754 (2000)		

Parky 2/26/04




Sheet 8 of 8

FORM PTO-1449
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT
BY APPLICANTATTY. DOCKET NO.:
CV01489K
SERIAL NO.:
10/057,323
APPLICANT:
Harry R. Davis
FILING DATE:
January 25, 2002
GROUP:
1619

(Use several sheets if necessary)

87	NC	Van Heek <i>et al.</i> , 2000, "The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically", <i>XII International Symposium of Atherosclerosis, Stockholm Sweden</i> (June 25-29, 2000)
	N D	Iannucci <i>et al.</i> , "Metabolism of SCH 58235 in the Human, Rat and Dog", <i>47th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX</i> (June 13-17, 1999)
	NE	Reiss <i>et al.</i> , "An Enzymatic Synthesis of Glucuronides of Azetidinone-based Cholesterol Absorption Inhibitors", <i>Bioorganic & Medicinal Chemistry</i> , 7:2199-2202 (1999)
	NF	Rosenblum <i>et al.</i> , "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption", <i>J. Med. Chem.</i> 41:973-980 (1998)
	NG	Vaccaro <i>et al.</i> , "Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8:313-318 (1998)
	NH	Zaks <i>et al.</i> , "Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235", <i>Applied Biochemistry and Biotechnology</i> , 73:205-214 (1998)
	NI	W. Insull <i>et al.</i> , "Postmenopausal Hypercholesterolemic Women Derive Additive Benefit from Raloxifene and Simvastatin on Lipid Parameters", <i>World Heart Federation 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke - Abstract Book</i> , p. 35 (June 12-15, 2002)
	NJ	L. Simons <i>et al.</i> , 2002, "Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia: Efficacy and safety in patients with Type 2 diabetes mellitus", presented at the 38 th Annual Meeting of the EASD, September 1-5, 2002
	NK	C. Allain <i>et al.</i> , 1974, "Enzymatic Determination of Total Serum Cholesterol", <i>Clinical Chemical</i> , 20:470-475
	NL	R. Mayrhofer <i>et al.</i> , 1980, "Simple-Preparation of 3-Benzylidene-2-azetidinones", <i>Synthesis</i> , 247-248
	NM	Burrier, R.E. <i>et al.</i> , 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", <i>Biochemical Pharmacology</i> 47:1545-1551
	NN	Burrier, R.E. <i>et al.</i> , 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibitor on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 272:156-163
	NO	E.F. Binder <i>et al.</i> , "Effects of Hormone Replacement Therapy on Serum Lipids in Elderly Women. A Randomized, Placebo-Controlled Trial", <i>134 Ann. Intern. Med.</i> 9:754-760 (May 1, 2001)
	NP	MR Haymart <i>et al.</i> , "Optimal Management of Dyslipidemia in Women and Men", <i>2 J. Gend. Specif. Med.</i> 6:37-42 (Nov. - Dec. 1997)
	NQ	"Framingham Heart Study Analysis Reveals Some Primary Prevention Subgroups Are Being Overlooked", <i>Heartwire</i> (April 12, 2001)
	NR	"Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third Report of the National Cholesterol Education Program (NCEP)", <i>NIH Publication No. 01-3670</i> (May 2001)
	NS	Van Heek <i>et al.</i> , "Ezetimibe, A Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters", <i>50 Diabetes</i> 1330-1335 (June 2001)
	NT	"Additional Statins Show Anti-Inflammatory Effect", <i>103 Circulation</i> 1933-35 (April 17, 2001)
	NU	H. Hauser, <i>et al.</i> , "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine", <i>Biochemistry</i> 37:17843-17850, 1998
	NV	G. Salen, <i>et al.</i> , "Sitosterolemia", <i>Journal of Lipid Research</i> 33:945-955, 1992
54	NW	Stedman's Medical Dictionary, 27 th Edition, pg. 1381
DATE CONSIDERED		2/26/04



Sheet 1 of 4

FORM PTO-1470	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01489K	SERIAL NO.: 10/057,323
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: Harry R. Davis et al.	
		FILING DATE: January 25, 2002	GROUP: 1619


U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SH	AA	US2002/0132855	09/19/02	Nelson, et al.			
	AB	US2002/0137689	09/26/02	Glombik et al.			
	AC	US2002/0128253	09/12/02	Glombik et al.			
	AD	US2002/0039774	04/04/02	Kramer et al.			
	AE	US2002/0128252	09/12/02	Glombik et al.			
	AF	10/057,534	01/25/02	Harry R. Davis et al.			
	AG	10/057,646	01/25/02	Harry R. Davis et al.			
	AH	10/057,629	01/25/02	Harry R. Davis			
	AI	10/154,106	05/22/02	Harry R. Davis et al.			
	AJ	10/057,323	01/25/02	Harry R. Davis et al.			
	AK	10/136,968	05/01/02	Wing-Kee Philip Cho et al.			
	AL	10/057,339	01/25/02	Teddy Kosoglou et al.			
	AM	10/247,032	01/25/02	Harry R. Davis			
	AN	10/056,680	01/25/02	Teddy Kosoglou et al.			
	AO	10/247,099	09/19/02	Harry R. Davis et al.			
	AP	10/247,085	09/19/02	John T. Strony			
	AQ	10/247,095	09/19/02	Harry R. Davis			
	AR	10/246,996	09/19/02	Alexandre P. Lebeaut et al.			
	AS	10/247,397	09/19/02	Harry R. Davis et al.			
SH	AT	10/166,942	06/11/02	Anima Ghosal et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
SH	AU	BE 884722 A	12/01/80	BELGIUM	C07D	AG1K	X(abs.)	
	AV	CA 2253769	11/29/99	CANADA	A61K	31/22		
	AW	DE 2046823 A	03/30/72	GERMANY	C07C		X(abs.)	
	AX	DE 2521113 A	03/18/76	GERMANY	C07C	87/34	X(abs.)	
	AY	EP 0002151 A1,B1	05/30/79	EUROPE	C07C	69/67		
	AZ	EP 0010299 B1	02/15/84	EUROPE	A61K	45/06		
	BA	EP 0179559 A2	04/30/86	EUROPE	C07D	405/06		
	BB	EP 0199630 A1	10/29/86	EUROPE	C07D	205/08		
	BC	EP 0199630 B1	09/19/90	EUROPE	C07D	205/08		
	BD	EP 0264231 A1	04/20/88	EUROPE	C07D	205/08		
	BE	EP 0266896 B1	05/11/88	EUROPE	C07D	471/04		
	BF	EP 0274873 B1	07/20/88	EUROPE	C07K	11/00		
	BG	EP 0288973 B1	11/02/88	EUROPE	C07D	417/06		
	BH	EP 0311366 B1	04/12/89	EUROPE	C07D	471/04		
	BI	EP 0333268 A1	09/20/89	EUROPE	C07F	7/18		
	BJ	EP 0337549 A1	10/18/89	EUROPE	C07D	205/08		
	BK	EP 0337549 B1	10/04/95	EUROPE	C07D	205/08		
	BL	EP 0365364 A2	04/25/90	EUROPE	C07D	205/08		
	BM	EP 0369686 A1	05/23/90	EUROPE	C07D	463/00		
	BN	EP 0375527 A1	06/27/90	EUROPE	C07D	205/08	X(abs.)	
	BO	EP 0401705 A3	12/12/90	EUROPE	A61K	31/66		
	BP	EP 0415487 A2	03/06/91	EUROPE	C07D	205/08		
	BQ	EP 0455042 A1	11/06/91	EUROPE	A61K	31/19		
	BR	EP 0457514 A1	11/21/91	EUROPE	A61K	45/06		
	BS	EP 0457514 B1	08/21/96	EUROPE	A61K	45/06		
	BT	EP 0461548 A3	12/18/91	EUROPE	A61K	31/365		
SH	BU	EP 0462667 A2	12/27/91	EUROPE	C07D	205/08		

S. L. H. 2/26/04




FORM PTO-1449				U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01489K		SERIAL NO.: 10/057,323	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						APPLICANT: Harry R. Davis et al.			
						FILING DATE: January 25, 2002		GROUP: 1619	
87	BV	EP 0475148 A1	03/18/92	EUROPE	A61K	31/215			
	BW	EP 0475755 B1	03/18/92	EUROPE	C07D	403/06			
	BX	EP 0481671 A1	04/22/92	EUROPE	C07D	205/08			
	BY	EP 0482498 A3	04/29/92	EUROPE	A61K	31/66			
	BZ	EP 0524595 A1	01/27/93	EUROPE	C07D	205/08			
	CA	EP 0720599 B1	07/10/96	EUROPE	C07D	205/08			
	CB	EP 0793958 A2	09/10/97	EUROPE	A61K	9/16	X(abs.)		
	CC	EP 0814080 A1	12/29/97	EUROPE	C07D	267/14			
	CD	EP 0904781 A2	03/31/99	EUROPE	A61K	31/215			
	CE	EP 1048295 A2	11/02/00	EUROPE	A61K	31/216			
	CF	FR 1103113	10/31/55	FRANCE				X	
	CG	FR 2779347	12/10/97	FRANCE	A61	031/215	X(abs.)		
	CH	GB 861367	02/22/61	GB	A61K				
	CI	GB 902658	08/09/62	GB	C07D				
	CJ	GB 1415295	11/26/75	GB	C07C	59/26			
	CK	GB 2329334 A	03/24/99	GB	A61K	45/00			
	CL	JP 028057	10/01/81	JAPAN			X(abs.)		
	CM	JP 121479	12/10/86	JAPAN			X(abs.)		
	CN	JP 136485	05/26/81	JAPAN			X(abs.)		
	CO	JP 180212	03/24/86	JAPAN			X(abs.)		
	CP	JP 219681	04/14/87	JAPAN			X(abs.)		
	CQ	JP 5194209 A	08/03/93	JAPAN	A61K	031/22	X(abs.)		
	CR	JP 5239020 A	1993	JAPAN	C07D	205/08	X(abs.)		
	CS	JP 4054182 A	1992	JAPAN		017/16	X(abs.)		
	CT	JP 63017859 A	1988	JAPAN	C07D	205/08	X(abs.)		
	CU	JP 4266869 A	1992	JAPAN	C07D	205/08	X(abs.)		
	CV	JP 4356195 A	1993	JAPAN			X(abs.)		
	CW	JP 4356495	12/10/92	JAPAN			X(abs.)		
	CX	JP 5058993 A	1993	JAPAN			X(abs.)		
	CY	JP 61280295 A	1987	JAPAN			X(abs.)		
	CZ	JP 95051558 B2	06/05/95	JAPAN	C07D	205/08	X(abs.)		
	DA	JP 91068020	10/25/91	JAPAN	C07D	205/08	X(abs.)		
	DB	JP 94047573	06/22/94	JAPAN	C07D	205/08	X(abs.)		
	DC	WO 82/01649	05/27/82	PCT	A61K	9/52	X(abs.)		
	DD	WO 87/04429	07/30/87	PCT	C07D	205/08			
	DE	WO 88/04656	06/30/88	PCT	C07D	405/04			
	DF	WO 88/05296	07/28/88	PCT	A61K	31/365			
	DG	WO 91/03249	03/21/91	PCT	A61K	31/785	X(abs.)		
	DH	WO 92/13837	08/20/92	PCT	C07D	205/085			
	DI	WO 93/02048	02/04/93	PCT	C07D	205/08			
	DJ	WO 93/07167	04/15/93	PCT	C07J	71/00			
	DK	WO 93/11150	06/10/93	PCT	C07J	71/00			
	DL	WO 94/00480	01/06/94	PCT	C07J	71/00			
	DM	WO 94/14433	07/07/94	PCT	A61K	31/395			
	DN	WO 94/17038	08/04/94	PCT	C07D	205/12			
	DO	WO 94/20535	09/15/94	PCT	C07K	13/00			
	DP	WO 95/04533	02/16/95	PCT	A61K	31/445			
	DQ	WO 95/06470	03/09/95	PCT	A61K	31/435			
	DR	WO 95/08532	03/30/95	PCT	C07D	205/08			
	DS	WO 95/18143	07/6/95	PCT	C07J	71/00			
52	DT	WO 95/26334	10/05/95	PCT	C07D	205/08			

RECEIVED

MAR 13 2003

TECH CENTER 1600

Cahng 2/26/04

Sheet 3 of 4


U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO.: CV01489K		SERIAL NO.: 10/057,323	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT: Harry R. Davis et al.			
(Use several sheets if necessary)					FILING DATE: January 25, 2002		GROUP: 1619	
571	DU	WO 95/28919	11/02/95	PCT	A61K	31/19	X(abs.)	
	DV	WO 96/00288	01/04/96	PCT	C12N	15/12		
	DW	WO 96/09827	04/04/96	PCT	A61K	31/58		
	DX	WO 96/16037	05/30/96	PCT	C07D	205/08		
	DY	WO 96/19987	07/04/96	PCT	A61K	31/35		
	DZ	WO 96/40255	12/19/96	PCT	A61K	45/06		
	EA	WO 97/16455	05/09/97	PCT	C07H	3/04		
	EB	WO 97/18304	05/22/97	PCT	C12N	15/00		
	EC	WO 97/25042	07/17/97	PCT	A61K	31/42		
	ED	WO 97/28149	08/07/97	PCT	C07D	307/79		
	EE	WO 97/31907	09/04/97	PCT	C07D	263/56		
	EF	WO 97/35576	10/02/97	PCT	A61K	31/44		
	EG	WO 97/46238	12/11/97	PCT	A61K	31/245		
	EH	WO 98/01100	01/15/98	PCT	A61K			
	EI	WO 98/05331	02/12/98	PCT	A61K	31/45		
	EJ	WO 98/14179	04/09/98	PCT	A61K	9/50		
	EK	WO 98/31360	07/23/98	PCT	A61K	31/19		
	EL	WO 98/31361	07/23/98	PCT	A61K	31/215	X(abs.)	
	EM	WO 98/31366	07/23/98	PCT	A61K	31/445		
	EN	WO 98/43081	10/01/98	PCT	G01N	33/50		
	EO	WO 98/46215	10/22/98	PCT	A61K	9/20		
	EP	WO 98/47518	10/29/98	PCT	A61K	31/715		
	EQ	WO 98/57652	12/23/98	PCT	A61K	31/785		
	ER	WO 99/04815	04/02/99	PCT	A61K	45/00	X(abs.)	
	ES	WO 99/06035	02/11/99	PCT	A61K	31/00		
	ET	WO 99/06046	02/11/99	PCT	A61K	31/455		
	EU	WO 99/09967	03/04/99	PCT	A61K	31/00		
	EV	WO 99/12534	03/18/99	PCT	A61K	31/17	X(abs.)	
	EW	WO 99/11260	03/11/99	PCT	A61K	31/40		
	EX	WO 99/15159	04/01/99	PCT	A61K	31/00		
	EY	WO 99/15520	04/01/99	PCT	C07D	319/20	X(abs.)	
	EZ	WO 99/18072	04/15/99	PCT	C07D	205/08		
	FA	WO 99/20275	04/29/99	PCT	A61K	31/47		
	FB	WO 99/20614	04/29/99	PCT	C07D	265/36		
	FC	WO 99/29300	06/17/99	PCT	A61K	9/107		
	FD	WO 99/38498	08/05/99	PCT	A61K	31/00		
	FE	WO 99/38845	08/05/99	PCT	C07D	213/65		
	FF	WO 99/38850	08/05/99	PCT	C07D	237/32		
	FG	WO 99/46232	09/16/99	PCT	C07C	62/34	X(abs.)	
	FH	WO 99/47123	09/23/99	PCT	A61K	9/16		
	FI	WO 99/48488	09/30/99	PCT	A61K	31/00		
	FJ	WO 99/66929	12/29/99	PCT	A61K	31/405		
	FK	WO 99/66930	12/29/99	PCT	A61K	31/405		
	FL	WO 00/04011	01/27/00	PCT	C07D	319/06		
	FM	WO 00/07617	02/17/00	PCT	A61K	38/26		
571	FN	WO 00/16749	03/30/00	PCT	A61K	9/16	X(abs.)	

RECEIVED

MAR 13 2003

TECH CENTER 1800/2900

Pankaj 2/26/04

Sheet 4 of 4

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01489KSERIAL NO.:
10/057,323INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Harry R. Davis et al.FILING DATE:
January 25, 2002GROUP:
1619

(Use several sheets if necessary)

SH	FO	WO 00/18395	04/06/00	PCT	A61K	31/215		
	FP	WO 00/20623	04/13/00	PCT	C12P	41/00		
	FQ	WO 00/23415	04/27/00	PCT	C07C	69/734		
	FR	WO 00/23416	04/27/00	PCT	C07C	69/734		
	FS	WO 00/23425	04/27/00	PCT	C07D	209/80		
	FT	WO 00/23445	04/27/00	PCT	C07D	471/12		
	FU	WO 00/23451	04/27/00	PCT	C07D	487/14		
	FV	WO 00/28981	05/25/00	PCT	A61K	31/00		
	FW	WO 00/31548	06/02/00	PCT	G01N	33/68		
	FX	WO 00/32189	06/08/00	PCT	A61K	31/415		
	FY	WO 00/34240	06/15/00	PCT	C07D	205/08		
	FZ	WO 00/37057	06/29/00	PCT	A61K	9/48		
	GA	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)	
	GB	WO 00/38721	07/06/00	PCT	A61K	45/06		
	GC	WO 00/38722	07/06/00	PCT	A61K	45/06		
	GD	WO 00/38723	07/06/00	PCT	A61K	45/06		
SH	GE	WO 00/38724	07/06/00	PCT	A61K	45/06		

DATE CONSIDERED

30343

RECEIVED

MAR 13 2003

TECH CENTER 1600/2900


init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
41	P01	5827536	1998-10-27		Laruelle		
	P02	5827541	1998-10-27		Yarwood		
	P03	5831091	1998-11-03		Ohmizu		
	P04	5843984	1998-12-01		Clay		
	P05	5846966	1998-12-08		Rosenblum		
	P06	5847008	1998-12-08		Doebber		
	P07	5847115	1998-12-08		Iwasaki		
	P08	5851553	1998-12-22		Myers		
	P09	5856473	1999-01-05		Shankar		
	P10	5858409	1999-01-12		Karetny		
	P11	5859051	1999-01-12		Adams		
	P12	5862999	1999-01-26		Czekai		
	P13	5866163	1999-02-02		Myers		
	P14	5869098	1999-02-09		Misra		
	P15	5871781	1999-02-16		Myers		
	P16	5880148	1999-03-09		Edgar		
	P17	5883109	1999-03-16		Gregg		
54	P18	5886171	1999-03-23		Wu		

Signature
2/26/04

61	P19	5919672	1999-07-06		Homann
	P20	5925333	1999-07-20		Krieger
	P21	5952003	1999-09-14		Guentensberger
	P22	5952321	1999-09-14		Doherty
	P23	5959123	1999-09-28		Singh
	P24	5972389	1999-10-26		Shell
	P25	5976570	1999-11-02		Greaves
	P26	5985936	1999-11-16		Novak
	P27	5990102	1999-11-23		Hickey
	P28	5998441	1999-12-07		Palkowitz
	P29	6027747	2000-02-22		Terracol
	P30	6043257	2000-03-28		Dominguez
	P31	6056975	2000-05-02		Mitra
	P32	6057342	2000-05-02		Fevig
	P33	6063764	2000-05-16		Creasey
	P34	6066653	2000-05-23		Gregg
	P35	6071899	2000-06-06		Hickey
	P36	6074670	2000-06-13		Stamm
54	P37	6080767	2000-06-27		Klein

P38	6080778	2000-06-27		Yankner
P39	6084082	2000-07-04		Ravikumar
P40	6090830	2000-07-18		Myers
P41	6090839	2000-07-18		Adams
P42	6093812	2000-07-25		Thiruvengadam
P43	6096883	2000-08-01		Wu
P44	6099865	2000-08-08		Augello
P45	6103705	2000-08-15		Uzan
P46	6110493	2000-08-29		Guentensberger
P47	6117429	2000-09-12		Bucci
P48	6133001	2000-10-17		Homann
P49	6139873	2000-10-31		Hughes
P50	6143885	2000-11-07		Choi



Signature

Examiner Name	Date
	2/26/24

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
SM	P01	2809194	1957-10-08		Novello		
	P02	3108097	1963-10-22		Ugi		
	P03	3152173	1964-10-06		Ehrhart		
	P04	3267104	1966-08-16		Hermans		
	P05	3399192	1968-08-27		Regnier		
	P06	3692895	1972-09-19		Nelson		
	P07	4148923	1979-04-10		Giudicelli		
	P08	4239763	1980-12-16		Milavec		
	P09	4567195	1986-01-28		Schwarz		
	P10	4626549	1986-12-02		Molloy		
	P11	4654362	1987-03-31		Lommen		
	P12	4680289	1987-07-14		Applezweig		
	P13	4937267	1990-06-26		Holloway		
	P14	5093365	1992-03-03		Berge		
	P15	5106833	1992-04-21		Broze		
	P16	5110730	1992-05-05		Edgington		
	P17	5120713	1992-06-09		Mugica		
	P18	5278176	1994-01-11		Lin		
	P19	5358852	1994-10-25		Wu		
	P20	5385885	1995-01-31		Gasic		
	P21	5703188	1997-12-30		Mandeville		
	P22	5994554	1999-11-30		Kliwer		
	P23	6008237	1999-12-28		Sahoo		
	P24	6028109	2000-02-22		Wilson		
	P25	6033656	2000-03-07		Mikami		
	P26	6040147	2000-03-21		Ridker		
	P27	6121319	2000-09-19		Somers		
SM	P28	6127424	2000-10-03		Martin		

SH	P29	6140354	2000-10-31		Dax
	P30	6147090	2000-11-14		DeNinno
	P31	6147109	2000-11-14		Liao
	P32	6147250	2000-11-14		Somers
	P33	6159997	2000-12-12		Tsujita
	P34	6162805	2000-12-19		Hefti
	P35	6166049	2000-12-26		Smith
	P36	6174665	2001-01-16		Dullien
	P37	6180138	2001-01-30		Engh
	P38	6180625	2001-01-30		Persson
	P39	6180660	2001-01-30		Whitney
	P40	6191117	2001-02-20		Kozachuk
	P41	6191159	2001-02-20		Pinto
	P42	6200998	2001-03-13		Sahoo
	P43	6207697	2001-03-27		Han
	P44	6207699	2001-03-27		Rothman
	P45	6207822	2001-03-27		Thiruvengadam
	P46	6214831	2001-04-10		Yokoo
	P47	6235706	2001-05-22		Gould
	P48	6245743	2001-06-12		Marlowe
	P49	6248781	2001-06-19		Jeppesen
SH	P50	6251852	2001-06-26		Gould

Signature

Examiner Name	Date
	

Electronic Information Disclosure Statement



COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS

Application:



10/057323

Confirmation: 1525

Applicant(s): Harry Davis

Docket
Number: CV01489K

Group Art Unit: 1617










Examiner: BAHAR, MOJDEH

search string: (6262042 or 6262047 or 6262098 or 6242605 or 6277584 or 6316029 or RE37721 or
H0001286).pn.


US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
SH	P01	6262042	2001-07-		Cook		

			17		
	P02	6262047	2001-07-17		Zhu
	P03	6262098	2001-07-17		Huebner
	P04	6242605	2001-06-05		Raveendranath
	P05	6277584	2001-08-21		Chu
	P06	6316029	2001-11-13		Jain
	P07	RE37721	2002-05-28		Rosenblum
	P08	H0001286	1994-02-01		Eisman


Signature

Examiner Name	Date
	2/26/04

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
SM	P01	5567439	1996-10-22		Myers		
	P02	5576014	1996-11-19		Mizumoto		
	P03	5587172	1996-12-24		Cherukuri		
	P04	5587180	1996-12-24		Allen		
	P05	5591456	1997-01-07		Franson		
	P06	5593971	1997-01-14		Tschollar		
	P07	5595761	1997-01-21		Allen		
	P08	5607697	1997-03-04		Alkire		
	P09	5612353	1997-03-18		Ewing		
	P10	5612367	1997-03-18		Timko		
	P11	5612378	1997-03-18		Tianbao		
	P12	5618707	1997-04-08		Homann		
	P13	5622719	1997-04-22		Myers		
	P14	5622985	1997-04-22		Olukotun		
	P15	5624920	1997-04-29		McKittrick		
	P16	5627176	1997-05-06		Kirkup		
	P17	5631023	1997-05-20		Kearney		
	P18	5631365	1997-05-20		Rosenblum		
	P19	5633246	1997-05-27		McKittrick		
	P20	5635210	1997-06-03		Allen		
	P21	5639475	1997-06-17		Bettman		
	P22	5639739	1997-06-17		Dominguez		
	P23	5656624	1997-08-12		Vaccaro		
	P24	5661145	1997-08-26		Davis		
	P25	5674893	1997-10-07		Behounek		
	P26	5688785	1997-11-18		Vaccaro		
	P27	5688787	1997-11-18		Burnett		
SM	P28	5688990	1997-11-18		Shankar		

21	P29	5691375	1997-11-25		Behounek
	P30	5698527	1997-12-16		Kim
	P31	5698548	1997-12-16		Dugar
	P32	5703234	1997-12-30		Iwasaki
	P33	5709886	1998-01-20		Bettman
	P34	5718388	1998-02-17		Czekai
	P35	5728827	1998-03-17		Kannapan
	P36	5734077	1998-03-31		Regnier
	P37	5739321	1998-04-14		Wu
	P38	5744467	1998-04-28		McKittrick
	P39	5747001	1998-05-05		Wiedmann
	P40	5753254	1998-05-19		Khan
	P41	5756470	1998-05-26		Yumibe
	P42	5759865	1998-06-02		Bruns
	P43	5767115	1998-06-16		Rosenblum
	P44	5776491	1998-07-07		Allen
	P45	5807576	1998-09-15		Allen
	P46	5807577	1998-09-15		Ouali
	P47	5807578	1998-09-15		Acosta-Cuello
	P48	5807834	1998-09-15		Morehouse
	P49	5808056	1998-09-15		Amato
FM	P50	5817806	1998-10-06		Rossi


Signature


Examiner Name	Date
	2/26/04

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
6/1	P01	4952689	1990-08-28		Kawashima		
	P02	4961890	1990-10-09		Boyer		
	P03	4983597	1991-01-08		Yang		
	P04	4990535	1991-02-05		Cho		
	P05	5030628	1991-07-09		Joyeau		
	P06	5073374	1991-12-17		McCarty		
	P07	5091525	1992-02-25		Brennan		
	P08	5099034	1992-03-24		Yoshida		
	P09	5100675	1992-03-31		Cho		
	P10	5112616	1992-05-12		McCarty		
	P11	5120729	1992-06-09		Chabala		
	P12	5130333	1992-07-14		Pan		
	P13	5145684	1992-09-08		Liversidge		
	P14	5157025	1992-10-22		Aberg		
	P15	5162117	1992-11-10		Stupak		
	P16	5178878	1993-01-12		Wehling		
	P17	5188825	1993-02-23		Iles		
	P18	5190970	1993-03-02		Pan		
	P19	5204461	1993-04-20		Murayama		
	P20	5219574	1993-06-15		Wehling		
	P21	5223264	1993-06-29		Wehling		
	P22	5229362	1993-07-20		Kirst		
	P23	5229381	1993-07-20		Doherty		
	P24	5229510	1993-07-20		Knight		
	P25	5260305	1993-11-09		Dennick		
	P26	5286631	1994-02-15		Boeck		
	P27	5298497	1994-03-29		Tschollar		
6/1	P28	5306817	1994-04-26		Thiruvengadam		

84	P29	5318767	1994-06-07		Liversidge
	P30	5348953	1994-09-20		Doherty
	P31	5350868	1994-09-27		Yoshida
	P32	5384124	1995-01-24		Courteille
	P33	5399363	1995-03-21		Liversidge
	P34	5401513	1995-03-28		Wehling
	P35	5412092	1995-05-02		Rey
	P36	5429824	1995-07-04		June
	P37	5446464	1995-08-29		Feldle
	P38	5461039	1995-10-24		Tschollar
	P39	5464632	1995-11-07		Cousin
	P40	5494683	1996-02-27		Liversidge
	P41	5503846	1996-04-02		Wehling
	P42	5510118	1996-04-23		Bosch
	P43	5510466	1996-04-23		Krieger
	P44	5518187	1996-05-21		Bruno
	P45	5518738	1996-05-21		Eickhoff
	P46	5545628	1996-08-13		Deboeck
	P47	5550229	1996-08-27		Iwasaki
	P48	5552160	1996-09-03		Liversidge
	P49	5561227	1996-10-01		Thiruvengadam
84	P50	5563264	1996-10-08		Kume

Signature

Examiner Name	Date
	2/24/04



init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
SM	P01	3716583	1973-02-13	[Barcode]	Nakamura		
	P02	3781328	1973-12-25	[Barcode]	Witte		
	P03	3948973	1976-04-06	[Barcode]	Phillips		
	P04	4072705	1978-02-07	[Barcode]	Mieville		
	P05	4075000	1978-02-21	[Barcode]	Abdulla		
	P06	4144232	1979-03-13	[Barcode]	Koppel		
	P07	4166907	1979-09-04	[Barcode]	Krapcho		
	P08	4178695	1979-12-18	[Barcode]	Erbeia		
	P09	4179515	1979-12-18	[Barcode]	Mieville		
	P10	4235896	1980-11-25	[Barcode]	Mieville		
	P11	4250191	1981-02-10	[Barcode]	Edwards		
	P12	4260743	1981-04-07	[Barcode]	Bose		
	P13	4304718	1981-12-08	[Barcode]	Kamiya		
	P14	4375475	1983-03-01	[Barcode]	Willard		
	P15	4443372	1984-04-17	[Barcode]	Luo		
	P16	4444784	1984-04-24	[Barcode]	Hoffman		
	P17	4472309	1984-09-18	[Barcode]	Kamiya		
	P18	4479900	1984-10-30	[Barcode]	Luo		
	P19	4500456	1985-02-19	[Barcode]	Spitzer		
	P20	4534786	1985-08-13	[Barcode]	Luo		
	P21	4564609	1986-01-14	[Barcode]	Tamura		
	P22	4576748	1986-03-18	[Barcode]	Greenlee		
	P23	4576749	1986-03-18	[Barcode]	Zahler		
	P24	4576753	1986-03-18	[Barcode]	Kamiya		
	P25	4581170	1986-04-08	[Barcode]	Mueller		
	P26	4595532	1986-06-17	[Barcode]	Miller		
	P27	4602003	1986-07-22	[Barcode]	Malinow		
SM	P28	4602005	1986-07-22	[Barcode]	Malinow		

RECEIVED
AUG 15 2002
TECH CENTER 1600/2900

Signature

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900



P29	4614614	1986-09-30		Ernest
P30	4616047	1986-10-07		Lafon
P31	4620867	1986-11-04		Luo
P32	4633017	1986-12-30		Mueller
P33	4642903	1987-02-17		Davies
P34	4675399	1987-06-23		Miller
P35	4680391	1987-07-14		Firestone
P36	4739101	1988-04-19		Bourgogne
P37	4778883	1988-10-18		Yoshioka
P38	4784734	1988-11-15		Torii
P39	4794108	1988-12-27		Kishimoto
P40	4800079	1989-01-24		Boyer
P41	4803266	1989-02-07		Kawashima
P42	4834846	1989-05-30		Abramson
P43	4814354	1989-03-21		Ghebre-Sellassie
P44	4834846	1989-05-30		Abramson
P45	4871752	1989-10-03		Ilg
P46	4876365	1989-10-24		Kirkup
P47	4879301	1989-11-07		Umio
P48	4895726	1990-01-23		Curtet
P49	4925672	1990-05-15		Gremm
P50	4939248	1990-07-03		Yoshioka

[Signature] 2/26/04

Published Applications

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
------	--------------	---------------	------	----------	----------	-------	----------

U01	20010028895	2001-10-11		Bisgaier
U02	20020006919	2002-01-17		Thosar

RECEIVED
AUG 15 2002
TECH CENTER 1600/2900



Signature

Examiner Name	Date
<i>Patricia H.</i>	2/26/04